Our team is happy and proud to have been voted as the winner for pitching our MTHFD1/2 inhibitor program.
https://www.linkedin.com/feed/update/urn:li:activity:6948268990171365376
One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe
One-carbon therapeutics AB is discussing the ODIN trial with several
